Kidney protection beyond diabetes

SGLT2 inhibitors have become a cornerstone of type 2 diabetes therapy not for their antihyperglycaemic potency, but for their cardiovascular and renal benefits. In this Gamechangers episode, Professor Luigi Gnudi presents a pivotal study that found the renoprotective effects of this class of drugs also in people without diabetes. Watch Luigi Gnudi’s conclusions for future management of chronic kidney disease in the episode below.